BeiGene Debt Issuance/Retirement Net - Total 2014-2024 | ONC
BeiGene annual/quarterly debt issuance/retirement net - total history and growth rate from 2014 to 2024. Debt issuance/retirement net - total can be defined as the total amount of short term and long term borrowings repaid and issued.
- BeiGene debt issuance/retirement net - total for the quarter ending September 30, 2024 was $0.158B, a 827.47% increase year-over-year.
- BeiGene debt issuance/retirement net - total for the twelve months ending September 30, 2024 was $0.829B, a 7623.15% increase year-over-year.
- BeiGene annual debt issuance/retirement net - total for 2023 was $0.361B, a 647.15% decline from 2022.
- BeiGene annual debt issuance/retirement net - total for 2022 was $-0.066B, a 164.94% decline from 2021.
- BeiGene annual debt issuance/retirement net - total for 2021 was $0.102B, a 61.08% decline from 2020.
BeiGene Annual Debt Issuance/Retirement Net - Total
(Millions of US $) |
| 2023 |
$361 |
| 2022 |
$-66 |
| 2021 |
$102 |
| 2020 |
$261 |
| 2019 |
$35 |
| 2018 |
$34 |
| 2017 |
$133 |
| 2016 |
$12 |
| 2015 |
$6 |
| 2014 |
$52 |
| 2013 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
